Latest Close
₹927.65
+4.71%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹834.25
200 DMA
₹737.87
1 year gain / loss
+₹93.00(+11.14%)
₹834.65 → ₹927.65· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Sep 2026 · Consolidated figures where available
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives, based in India. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Market Cap
₹7,922.24 Cr
P/E
30.86×
Sector -38.72× · above
P/B
3.51×
Sector 4.11× · below
EV / EBITDA
17.06×
Sector 19.14× · below
ROE
8.22%
Sector 0.37%
ROCE
9.59%
Sector 6.55%
ROA
7.37%
Sector -17.04%
Cash Flow / Profit
1.50×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Sep 2026 | 610.92 +13.9% | 94.99 | 71.47 -6.1% |
| Jun 2026 | 536.25 -9.2% | 101.06 | 76.14 +24.6% |
| Mar 2026 | 590.69 +36.8% | 81.68 | 61.12 +27.4% |
| Dec 2025 | 431.9 | 62.87 | 47.96 |
Dividend
15 Sep 2026 · ₹2
Dividend
16 Feb 2026 · ₹1.5